ALFA Filings
Every announcement, straight from the exchange
Every Lupin other announcement announcement on NSE and BSE, newest first, each with its own page.
Time
7 announcements with these filters
Lupin Limited received an ESG rating of 70 for FY26 from NSE Sustainability Ratings and Analytics. The assessment was independently prepared using publicly available information.
Lupin Limited received an ESG rating of '60' ('Adequate' category) from ESG Risk Assessments & Insights Limited, which was assigned independently without company engagement.
Lupin Ltd has submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the period ended June 30, 2026. This disclosure details the current equity distribution structure.
Lupin Limited announced that the acquisition of minority shareholding in Multicare Pharmaceuticals Philippines is ongoing. Completion is now expected in July 2026, pending closing conditions.
Lupin shared positive Phase 1 trial results for its novel SOS1 inhibitor, LNP8701, at ASCO 2026. The drug demonstrated safety and favorable anti-tumor activity in metastatic patients.
Lupin Limited filed its Annual Secretarial Compliance Report for FY2026. The report by Makarand M. Joshi & Co. confirms regulatory adherence with no major non-compliances noted.
Lupin debuted in the Dow Jones Best-in-Class Indices for 2026. This prestigious inclusion recognizes the company's industry-leading ESG performance and sustainability leadership.